Alembic Pharma gets USFDA’s nod for Tobramycin Ophthalmic Solution

22 Apr 2019 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tobramycin Ophthalmic Solution USP, 0.3%. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Tobrex Ophthalmic Solution, 0.3%, of Novartis Pharmaceuticals Corporation.

Tobramycin Ophthalmic Solution USP, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Tobramycin Ophthalmic Solution USP, 0.3% have an estimated market size of $9.6 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 92 ANDA approvals (80 final approvals and 12 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

775.30 -13.90 (-1.76%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×